Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2017

View Archived Issues

Connexin 43 shows promise as a potential target for treating sepsis

BioCryst reports second interim analysis data from its APeX-1 phase II trial of BCX-7353

Phase I results support further study of Trovagene's PCM-075 in AML

ContraFect begins phase II study of CF-301 in S. aureus bacteremia

FDA awards orphan drug designation to EB-101 from Abeona Therapeutics

ProMIS Neurosciences selects second lead product for Alzheimer's disease

Suven Life Sciences initiates phase I trial of SUVN-911

Protagonist Therapeutics commences phase I study of hepcidin mimetic peptide

Merck & Co. and Teijin Pharma enter agreement to develop antibody targeting tau

U.S. researchers develop murine model of Crimean-Congo hemorrhagic fever

GlaxoSmithKline initiates enrollment in first-in-human study of GSK-3352589

Novel PDGFR inhibitor PK-10571 shows promise in a model of pulmonary arterial hypertension

X4 Pharmaceuticals gives update on phase I/II study of X4P-001 in RCC

Myrcludex B granted EMA PRIME eligibility

Celgene's CC-90001 preferentially targets JNK1, advances in clinical development

Arena initiates phase IIa study of APD-371 for abdominal pain in Crohn's disease

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents TLR7 agonists

Jiangsu Hansoh/Shanghai Hansoh discover novel antiviral compounds

Cip1-interacting zinc finger protein is a useful biomarker of early-stage lung cancer

Respiratory disease model for enterovirus d68 developed in mice

Study evaluating NY-ESO SPEAR T cells plus pembrolizumab begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.